Systematic Financial Management LP Sells 4,195 Shares of Hill-Rom Holdings, Inc. (NYSE:HRC)

Systematic Financial Management LP decreased its holdings in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 31.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,950 shares of the medical technology company’s stock after selling 4,195 shares during the period. Systematic Financial Management LP’s holdings in Hill-Rom were worth $936,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HRC. Geode Capital Management LLC lifted its stake in Hill-Rom by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 647,698 shares of the medical technology company’s stock worth $57,353,000 after acquiring an additional 26,781 shares in the last quarter. Legacy Advisors LLC acquired a new position in Hill-Rom during the 1st quarter worth about $70,000. We Are One Seven LLC lifted its stake in Hill-Rom by 97.4% during the 1st quarter. We Are One Seven LLC now owns 2,089 shares of the medical technology company’s stock worth $221,000 after acquiring an additional 1,031 shares in the last quarter. Gateway Investment Advisers LLC lifted its stake in Hill-Rom by 2.1% during the 1st quarter. Gateway Investment Advisers LLC now owns 28,611 shares of the medical technology company’s stock worth $3,029,000 after acquiring an additional 600 shares in the last quarter. Finally, First Citizens Bank & Trust Co. lifted its stake in Hill-Rom by 38.3% during the 1st quarter. First Citizens Bank & Trust Co. now owns 4,596 shares of the medical technology company’s stock worth $487,000 after acquiring an additional 1,273 shares in the last quarter. Hedge funds and other institutional investors own 81.52% of the company’s stock.

In other news, SVP Deborah Rasin sold 5,500 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $103.00, for a total value of $566,500.00. Following the transaction, the senior vice president now owns 20,939 shares in the company, valued at approximately $2,156,717. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.73% of the company’s stock.

Several equities analysts recently issued reports on the company. Barclays increased their target price on Hill-Rom from $108.00 to $116.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $125.00 price target on shares of Hill-Rom in a research report on Tuesday, August 6th. ValuEngine lowered Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. KeyCorp increased their price target on Hill-Rom from $114.00 to $125.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Finally, Zacks Investment Research raised Hill-Rom from a “hold” rating to a “buy” rating and set a $103.00 price target on the stock in a research report on Thursday, June 6th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Hill-Rom currently has an average rating of “Buy” and a consensus target price of $112.43.

Shares of HRC traded down $1.12 during mid-day trading on Friday, reaching $106.17. The company’s stock had a trading volume of 381,603 shares, compared to its average volume of 431,854. Hill-Rom Holdings, Inc. has a 12-month low of $81.82 and a 12-month high of $109.18. The firm has a market capitalization of $7.17 billion, a PE ratio of 22.35, a PEG ratio of 2.12 and a beta of 0.90. The company has a current ratio of 1.51, a quick ratio of 1.14 and a debt-to-equity ratio of 1.12. The firm’s 50 day moving average price is $105.25.

Hill-Rom (NYSE:HRC) last released its quarterly earnings data on Friday, August 2nd. The medical technology company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.02. Hill-Rom had a return on equity of 21.26% and a net margin of 7.45%. The business had revenue of $726.80 million for the quarter, compared to the consensus estimate of $718.08 million. During the same quarter in the prior year, the business posted $1.15 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Sell-side analysts forecast that Hill-Rom Holdings, Inc. will post 5.05 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Friday, September 20th will be issued a $0.21 dividend. The ex-dividend date of this dividend is Thursday, September 19th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.79%. Hill-Rom’s payout ratio is currently 17.68%.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Article: What is the formula for the cash asset ratio?

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.